Drug Trial Radar · NCT03405818
An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
Last checked: Nov 20, 2026Latest source record: Apr 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Oct 22, 2015
Primary completion
Jul 27, 2017
Study completion Jul 27, 2017
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 72 months, up to 203 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an open-label study to evaluate the safety and pharmacokinetics of tavaborole 5% topical solution in treating distal subungual onychomycosis (a fungal infection) of the toenail in children and adolescents (ages 6 to 16 years). Following confirmation of eligibility, including laboratory evidence of a fungal organism in the toenail, tavaborole topical solution was applied once daily to all affected toenails for a 48-week treatment period. Clinical assessment of the extent of infection and safety assessments were performed periodically throughout the 48-week treatment period, and again at 52 weeks (4 weeks after stopping the treatment). A subgroup of enrolled subjects applied the topical solution to all 10 toenails and a small area of surrounding skin during the first 28 days. These subjects had blood samples analyzed to evaluate the pharmacokinetics (how the drug moves in the body) of tavaborole topical solution in children and adolescents.
Conditions
- Onychomycosis
- Tinea Unguium
Interventions
Tavaborole 5% Topical SolutionDrug
topical solution for application to toenails
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Local Tolerability Reactions by SeverityTime frame: Baseline up to Week 52
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to 28 days after last dose of study drug (up to Week 52)
- Number of Participants With Adverse Events (AEs) By SeverityTime frame: Baseline up to 28 days after last dose of study drug (up to Week 52)
- Change From Baseline in Hematology Parameters (Leukocytes: Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Hematology Parameters (Leukocytes: Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils) at Week 52Time frame: Baseline, Week 52
- Change From Baseline in Hematology Parameter (Hematocrit) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Hematology Parameter (Hematocrit) at Week 52Time frame: Baseline, Week 52
- Change From Baseline in Hematology Parameter (Erythrocytes) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Hematology Parameter (Erythrocytes) at Week 52Time frame: Baseline, Week 52
- Change From Baseline in Hematology Parameters (Hemoglobin) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Hematology Parameters (Hemoglobin) at Week 52Time frame: Baseline, Week 52
- Change From Baseline in Hematology Parameters (Leukocytes and Platelets) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Hematology Parameters (Leukocytes and Platelets) at Week 52Time frame: Baseline, Week 52
- Change From Baseline in Chemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase and Aspartate Aminotransferase) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Chemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase and Aspartate Aminotransferase) at Week 52Time frame: Baseline, Week 52
- Change From Baseline in Chemistry Parameters (Albumin and Protein) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Chemistry Parameters (Albumin and Protein) at Week 52Time frame: Baseline, Week 52
- Change From Baseline in Chemistry Parameters (Bilirubin, Creatinine, Glucose [Non-fasting] and Urea Nitrogen) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Chemistry Parameters (Bilirubin, Creatinine, Glucose [Non-fasting] and Urea Nitrogen) at Week 52Time frame: Baseline, Week 52
- Change From Baseline in Chemistry Parameters (Potassium and Sodium) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Chemistry Parameters (Potassium and Sodium) at Week 52Time frame: Baseline, Week 52
- Change From Baseline in Vital Sign (Blood Pressure) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Vital Sign (Blood Pressure) at Week 52Time frame: Baseline, Week 52
- Change From Baseline in Vital Sign (Pulse Rate) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Vital Sign (Pulse Rate) at Week 52Time frame: Baseline, Week 52
- Change From Baseline in Vital Sign (Respiratory Rate) at Week 24Time frame: Baseline, Week 24
- Change From Baseline in Vital Sign (Respiratory Rate) at Week 52Time frame: Baseline, Week 52
- Percentage of Participants With Complete Cure of Target Great Toenail (TGT) at Week 52Time frame: Week 52
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Madera Family Medical Group
Madera, California
Stanford University School of Medicine
Palo Alto, California
MedStar Health Research Institute - MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Doctors Research Network
South Miami, Florida
University Hospital, SUNY Downstate Medical Center
Brooklyn, New York
Skin Specialty Dermatology
New York, New York
Cyn3rgy Research
Gresham, Oregon
Oregon Dermatology & Research Center
Portland, Oregon
West Houston Clinical Research Services LLC
Houston, Texas
Texas Dermatology and Laser Specialists
San Antonio, Texas
Jordan Valley Dermatology Center
West Jordan, Utah
PI Coor Clinical Research, LLC
Burke, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.